Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Other Topics

Abstract A068: Determinants of efficacy in cancer immunovirotherapy

Rūta Veinalde, Christian Grossardt, Marie-Claude Bourgeois-Daigneault, Christof von Kalle, Dirk Jaeger, Guy Ungerechts and Christine E. Engeland
Rūta Veinalde
1National Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Grossardt
1National Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Claude Bourgeois-Daigneault
2Ottawa Hospital Research Institute, Centre for Innovative Cancer Research, Ottawa, ON, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christof von Kalle
1National Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Jaeger
3National Center for Tumor Diseases Heidelberg, Department of Medical Oncology, Heidelberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Ungerechts
3National Center for Tumor Diseases Heidelberg, Department of Medical Oncology, Heidelberg, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine E. Engeland
1National Center for Tumor Diseases Heidelberg, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.IMM2016-A068 Published November 2016
  • Article
  • Info & Metrics
Loading
Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY

Abstract

Replicating oncolytic viruses (OVs) are emerging as a promising therapeutic approach for different tumor entities. Positive data from numerous clinical studies are accumulating and as a first-in-class oncolytic herpes virus encoding GM-CSF, Talimogene Laherparepvec (T-VEC), has been approved for treatment of unresectable melanoma by the U.S. Food and Drug Administration at the end of 2015. Although it has been recognized that combinations of OVs with different immunomodulators can significantly improve therapeutic outcome, understanding of immune effector mechanisms determining success of a particular approach remains limited, restricting the development of rational combination strategies.

In this study we aimed to determine the most beneficial immunomodulation strategies for combination with oncolytic measles virus (MeV). Furthermore, we performed a comprehensive analysis of anti-tumor immune effector mechanisms associated with response to pinpoint mechanisms crucial for therapeutic efficacy. We developed MeV Schwarz vaccine strain vectors (MeVac) encoding different immunomodulators to target the main phases in establishment of an anti-tumor immune response: GM-CSF - to enhance maturation of antigen-presenting cells, an IL-12 fusion protein (FmIL-12) and IP-10 - to enhance immune effector cell responses, antibodies against CTLA-4 and PD-L1 and a soluble form of CD80 - to counteract immunosuppression in the tumor microenvironment. Therapeutic efficacy of the novel vectors was evaluated in the fully immunocompetent murine colon adenocarcinoma model MC38cea. MeVac encoding anti-PD-L1 and FmIL-12, respectively, were identified as the most effective therapeutics. Notably, MeVac encoding FmIL-12 showed a superior therapeutic efficacy, achieving 90% complete remissions of established tumors. Animals treated with the immunomodulatory MeVac vectors rejected secondary tumor engraftments, indicating establishment of protective anti-tumor immunity. Higher IFN-γ production upon restimulation of splenocytes with tumor cells in vitro was observed for animals treated with MeVac FmIL-12 in comparison to treatment with MeVac anti-PD-L1 and a control vector encoding constant region of antibody (MeVac IgG1-Fc), indicating establishment of a more potent memory response. Intratumoral cytokine profiling with cytokine bead arrays revealed upregulation of the effector cytokines IFN-γ and TNF-α after treatment with MeVac FmIL-12. A massive decrease in intratumoral natural killer (NK) cell counts and an increase of activation marker CD69 expression on NK cells as well as an increase in T cell amount was observed in flow cytometry analysis one day after treatment with MeVac FmIL-12. This indicates early direct activation of these lymphocyte subsets through direct IL-12 signaling. An increase in intratumoral T cells and a decrease in NK cells and activated cytotoxic T cells (CD8+CD69+) was observed four days after the last treatment with both MeVac anti-PD-L1 and MeVac IgG1-Fc, with slightly more pronounced effects in the MeVac anti-PD-L1 group. This suggests that MeVac vectors per se activate T and NK cell responses, which can further be supported with PD-L1 blockade.

This study establishes MeVac encoding FmIL-12 as a potent immunomodulatory oncolytic vector and provides insights into its mechanisms of action, thereby creating a basis for further rational vector modifications to translate immunomodulatory MeV into clinical application.

Citation Format: Rūta Veinalde, Christian Grossardt, Marie-Claude Bourgeois-Daigneault, Christof von Kalle, Dirk Jaeger, Guy Ungerechts, Christine E. Engeland. Determinants of efficacy in cancer immunovirotherapy [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A068.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (11 Supplement)
November 2016
Volume 4, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A068: Determinants of efficacy in cancer immunovirotherapy
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A068: Determinants of efficacy in cancer immunovirotherapy
Rūta Veinalde, Christian Grossardt, Marie-Claude Bourgeois-Daigneault, Christof von Kalle, Dirk Jaeger, Guy Ungerechts and Christine E. Engeland
Cancer Immunol Res November 1 2016 (4) (11 Supplement) A068; DOI: 10.1158/2326-6066.IMM2016-A068

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A068: Determinants of efficacy in cancer immunovirotherapy
Rūta Veinalde, Christian Grossardt, Marie-Claude Bourgeois-Daigneault, Christof von Kalle, Dirk Jaeger, Guy Ungerechts and Christine E. Engeland
Cancer Immunol Res November 1 2016 (4) (11 Supplement) A068; DOI: 10.1158/2326-6066.IMM2016-A068
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Other Topics

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
  • Abstract B197: Translational control in macrophages during inflammatory response
Show more Other Topics

Other Topics: Poster Presentations - Proffered Abstracts

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
  • Abstract B197: Translational control in macrophages during inflammatory response
Show more Other Topics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement